ProADM proven to be the best risk predictor
The new biomarker ProADM significantly improves risk assessment of patients suffering from lower respiratory tract infection (LRTI) An early risk assessment of LRTI patients is essential for optimizing treatment and rational resource allocation. Adrenomedullin (ADM) has a significant presence in the course of LRTI and is strongly associated with a patient’s risk of mortality and […]
